Fixed‐dose combination aclidinium/formoterol vs formoterol
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with formoterol (moderate certainty).
1 finding from 1 review
- Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes onlyOR 1.15 [0.82, 1.61]5 studies · 3140 participantsModerate